Mechanistically, CXCL2 interacts with Y‐Box Binding Protein 1 (YBX1) and prevents its nuclear translocation to reduce sterol regulatory element binding transcription factor 2 (SREBF2) transcription, leading to decreased cholesterol synthesis and a remodeled antitumor immune microenvironment that retards HCC progression. Here, CXCL2 is linked to hepatocellular carcinoma.